Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8+ effector T cell responses

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Raïch Regué, Dàlia ^a   Fabian, Kellsye P ^b   Watson, Alicia R ^a   Fecek, Ronald J ^b   Storkus, Walter J ^b   Thomson, Angus W ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

CD8+ T cells; cell activation; dendritic cells; melanoma; mTORC2

Indexed keywords

GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 12P70; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROGRAMMED DEATH 1 LIGAND 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL TRACKING; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; MALE; MELANOMA B16; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84976337078     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1146841     Document Type: Article

References (57)

1. S.Anguille, E.L.Smits, E.Lion, V.F.van Tendeloo, Z.N.Berneman. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014; 15:e257-e267; PMID:24872109; 10.1016/S1470-2045(13)70585-0.
2. K.Palucka, J.Banchereau. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; 10.1016/j.immuni.2013.07.004.
3. L.H.Butterfield. Dendritic cells in cancer immunotherapy clinical trials: are we making progress? Front Immunol 2013; 4:454; PMID:24379816; 10.3389/fimmu.2013.00454.
4. L.Galluzzi, L.Senovilla, E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, C.Sautès-Fridman, E.Tartour, L.Zitvogel, G.Kroemer. Trial watch: Dendritic cell-based interventions for cancer therapy. OncoImmunology 2012; 1:1111-34; PMID:23170259; 10.4161/onci.21494.
5. S.Mac Keon, M.S.Ruiz, S.Gazzaniga, R.Wainstok. Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol 2015; 6:243; PMID:26042126; 10.3389/fimmu.2015.00243.
6. Q.Yang, K.-L.Guan. Expanding mTOR signaling. Cell Res 2007; 17:666-81; PMID:17680028; 10.1038/cr.2007.64.
7. A.W.Thomson, H.R.Turnquist, G.Raimondi. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9:324-37; PMID:19390566; 10.1038/nri2546.
8. J.D.Powell, G.M.Delgoffe. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 2010; 33:301-11; PMID:20870173; 10.1016/j.immuni.2010.09.002.
9. D.D.Sarbassov, S.M.Ali, D.-H.Kim, D.A.Guertin, R.R.Latek, H.Erdjument-Bromage, P.Tempst, D.M.Sabatini. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol CB 2004; 14:1296-302; PMID:15268862; 10.1016/j.cub.2004.06.054.
10. D.A.Guertin, D.M.Sabatini. The pharmacology of mTOR inhibition. Sci Signal 2009; 2:pe24; PMID:19383975; 10.1126/scisignal.267pe24.
11. M.Laplante, D.M.Sabatini. mTOR signaling in growth control and disease. Cell 2012; 149:274-93; PMID:22500797; 10.1016/j.cell.2012.03.017.
12. S.Huang, P.J.Houghton. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs Lond Engl 2000 2002; 3:295-304; PMID:25231953; 10.1093/annonc/mdu456
13. M.Piccart, G.N.Hortobagyi, M.Campone, K.I.Pritchard, F.Lebrun, Y.Ito, S.Noguchi, A.Perez, H.S.Rugo, I.Deleu et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol Off J Eur Soc Med Oncol ESMO 2014; 25:2357-62; 10.1093/annonc/mdu456.
14. J.Chan, M.Kulke. Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr Treat Options Oncol 2014; 15:365-79; PMID:25092520; 10.1007/s11864-014-0294-4.
15. S.-Y.Sun. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett 2013; 340:1-8; PMID:23792225; 10.1016/j.canlet.2013.06.017.
16. R.E.Ashworth, J.Wu. Mammalian target of rapamycin inhibition in hepatocellular carcinoma. World J Hepatol 2014; 6:776-82; PMID:25429315; 10.4254/wjh.v6.i11.776.
17. H.Pópulo, J.M.Lopes, P.Soares. The mTOR signalling pathway in human cancer. Int J Mol Sci 2012; 13:1886-918; 10.3390/ijms13021886.
18. W.Damsky, G.Micevic, K.Meeth, V.Muthusamy, D.P.Curley, M.Santhanakrishnan, I.Erdelyi, J.T.Platt, L.Huang, N.Theodosakis et al. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell 2015; 27:41-56; PMID:25584893; 10.1016/j.ccell.2014.11.014.
19. J.Werzowa, S.Koehrer, S.Strommer, D.Cejka, T.Fuereder, E.Zebedin, V.Wacheck. Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. J Invest Dermatol 2011; 131:495-503; PMID:21048785; 10.1038/jid.2010.327.
20. A.L.Ho, E.Musi, G.Ambrosini, J.S.Nair, S.Deraje Vasudeva, E.de Stanchina, G.K.Schwartz. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PloS One 2012; 7:e40439; PMID:22808163; 10.1371/journal.pone.0040439.
21. Y.N.V.Gopal, H.Rizos, G.Chen, W.Deng, D.T.Frederick, Z.A.Cooper, R.A.Scolyer, G.Pupo, K.Komurov, V.Sehgal et al. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1 and oxidative phosphorylation in melanoma. Cancer Res 2014; 74:7037-47; PMID:25297634; 10.1158/0008-5472.CAN-14-1392.
22. D.Raïch-Regué, B.R.Rosborough, A.R.Watson, M.J.McGeachy, H.R.Turnquist, A.W.Thomson. mTORC2 deficiency in myeloid dendritic cells enhances their allogeneic Th1 and Th17 stimulatory ability after TLR4 ligation in vitro and in vivo. J Immunol 2015; 194:4767-76; PMID:25840913; 10.4049/jimmunol.1402551.
23. B.M.Carreno, M.Becker-Hapak, A.Huang, M.Chan, A.Alyasiry, W.-R.Lie, R.L.Aft, L.A.Cornelius, K.M.Trinkaus, G.P.Linette. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest 2013; 123:3383-94; PMID:23867552; 10.1172/JCI68395.
24. W.Lasek, R.Zagożdżon, M.Jakobisiak. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother CII 2014; 63:419-35; PMID:24514955; 10.1007/s00262-014-1523-1.
25. D.S.Vinay, E.P.Ryan, G.Pawelec, W.H.Talib, J.Stagg, E.Elkord, T.Lichtor, W.K.Decker, R.L.Whelan, H.M.C.S.Kumara et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol 2015; 35:S185–S198; PMID:25818339; 10.1016/j.semcancer.2015.03.004.
26. D.I.Gabrilovich, S.Ostrand-Rosenberg, V.Bronte. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; 10.1038/nri3175.
27. V.Umansky, A.Sevko. Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol 2012; 22:319-26; PMID:22349515; 10.1016/j.semcancer.2012.02.003.
28. L.Spel, J.-J.Boelens, S.Nierkens, M.Boes. Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation. Oncoimmunology 2013; 2:e26403; PMID:24482744; 10.4161/onci.26403.
29. C.Yang, H.Lee, S.Pal, V.Jove, J.Deng, W.Zhang, D.S.B.Hoon, M.Wakabayashi, S.Forman, H.Yu. B cells promote tumor progression via STAT3 regulated-angiogenesis. PloS One 2013; 8:e64159; PMID:23734190; 10.1371/journal.pone.0064159.
30. A.Mamalis, M.Garcha, J.Jagdeo. Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res 2014; 306:511-9; PMID:24615548; 10.1007/s00403-014-1457-7.
31. E.Amiel, B.Everts, T.C.Freitas, I.L.King, J.D.Curtis, E.L.Pearce, E.J.Pearce. Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice. J Immunol 2012; 189:2151-8; PMID:22826320; 10.4049/jimmunol.1103741.
32. J.J.Nordlund, J.M.Kirkwood, B.M.Forget, G.Milton, D.M.Albert, A.B.Lerner. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983; 9:689-96; PMID:6643767; 10.1016/S0190-9622(83)70182-9.
33. A.K.Palucka, H.Ueno, J.Connolly, F.Kerneis-Norvell, J.-P.Blanck, D.A.Johnston, J.Fay, J.Banchereau. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 2006; 29:545-57; PMID:16971810; 10.1097/01.cji.0000211309.90621.8b.
34. U.Keilholz, J.Weber, J.H.Finke, D.I.Gabrilovich, W.M.Kast, M.L.Disis, J.M.Kirkwood, C.Scheibenbogen, J.Schlom, V.C.Maino et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002; 25:97-138; PMID:12074049; 10.1097/00002371-200203000-00001.
35. J.M.Kirkwood, S.Lee, S.J.Moschos, M.R.Albertini, J.C.Michalak, C.Sander, T.Whiteside, L.H.Butterfield, L.Weiner. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 2009; 15:1443-51; PMID:19228745; 10.1158/1078-0432.CCR-08-1231.
36. C.Schaefer, L.H.Butterfield, S.Lee, G.G.Kim, C.Visus, A.Albers, J.M.Kirkwood, T.L.Whiteside. Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). Int J Cancer 2012; 131:874-84; PMID:22021080; 10.1002/ijc.26481.
37. M.K.Gately, A.G.Wolitzky, P.M.Quinn, R.Chizzonite. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 1992; 143:127-42; PMID:1352483; 10.1016/0008-8749(92)90011-D.
38. G.Trinchieri. Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol 1998; 16:365-96; PMID:9505196; 10.3109/08830189809043002.
39. H.Okada, P.Kalinski, R.Ueda, A.Hoji, G.Kohanbash, T.E.Donegan, A.H.Mintz, J.A.Engh, D.L.Bartlett, C.K.Brown et al. Induction of CD8+ T-Cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with type-1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011; 29:330-6; PMID:21149657; 10.1200/JCO.2010.30.7744.
40. B.Ruffell, D.Chang-Strachan, V.Chan, A.Rosenbusch, C.M.T.Ho, N.Pryer, D.Daniel, E.S.Hwang, H.S.Rugo, L.M.Coussens. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 2014; 26:623-37; PMID:25446896; 10.1016/j.ccell.2014.09.006.
41. P.Verdijk, E.H.J.G.Aarntzen, W.J.Lesterhuis, A.C.I.Boullart, E.Kok, M.M.van Rossum, S.Strijk, F.Eijckeler, J.J.Bonenkamp, J.F.M.Jacobs et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 2009; 15:2531-40; PMID:19318472; 10.1158/1078-0432.CCR-08-2729.
42. L.Chen, J.L.Taylor, N.C.Sabins, D.B.Lowe, Y.Qu, Z.You, W.J.Storkus. Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells. Cancer Gene Ther 2013; 20:469-77; PMID:23846252; 10.1038/cgt.2013.42.
43. J.L.Messina, D.A.Fenstermacher, S.Eschrich, X.Qu, A.E.Berglund, M.C.Lloyd, M.J.Schell, V.K.Sondak, J.S.Weber, J.J.Mulé. Twelve-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2012; 2:765; PMID:23097687; 10.1038/srep00765.
44. L.Chen, K.L.Fabian, J.L.Taylor, W.J.Storkus. Therapeutic use of dendritic cells to promote the extranodal priming of anti-tumor immunity. Front Immunol 2013; 4:388; PMID:24348473; 10.3389/fimmu.2013.00388
45. J.Brown, H.Wang, J.Suttles, D.T.Graves, M.Martin. Mammalian target of rapamycin complex 2 (mTORC2) negatively regulates Toll-like receptor 4-mediated inflammatory response via FoxO1. J Biol Chem 2011; 286:44295-305; PMID:22045807; 10.1074/jbc.M111.258053.
46. W.-C.Wei, C.-P.Liu, W.-C.Yang, L.-F.Shyur, J.-H.Sheu, S.-S.Chen, N.-S.Yang. Mammalian target of rapamycin complex 2 (mTORC2) regulates LPS-induced expression of IL-12 and IL-23 in human dendritic cells. J Leukoc Biol 2015; 97:1071-80; PMID:25877925; 10.1189/jlb.2A0414-206RR.
47. Q.Jiang, J.M.Weiss, T.Back, T.Chan, J.R.Ortaldo, S.Guichard, R.H.Wiltrout. mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. Cancer Res 2011; 71:4074-84; PMID:21540234; 10.1158/0008-5472.CAN-10-3968.
48. D.B.Lowe, A.Bose, J.L.Taylor, H.Tawbi, Y.Lin, J.M.Kirkwood, W.J.Storkus. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology 2014; 3:e27589; PMID:24734217; 10.4161/onci.27589.
49. K.B.Kim. Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma? Cancer 2013; 119:477-80; PMID:22915026; 10.1002/cncr.27756.
50. A.P.Algazi, E.Cha, S.M.Ortiz-Urda, T.McCalmont, B.C.Bastian, J.Hwang, M.H.Pampaloni, S.Behr, K.Chong, B.Cortez et al. The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. Br J Cancer 2015; 112:1326-31; PMID:25867272; 10.1038/bjc.2014.541.
51. N.Chi Sabins, J.L.Taylor, K.P.Fabian, L.J.Appleman, J.K.Maranchie, D.B.Stolz, W.J.Storkus. DLK1: A novel target for immunotherapeutic remodeling of the tumor blood vasculature. Mol Ther 2013; 21:1958-68; PMID:23896726; 10.1038/mt.2013.133.
52. J.L.Perez-Gracia, S.Labiano, M.E.Rodriguez-Ruiz, M.F.Sanmamed, I.Melero. Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Curr Opin Immunol 2014; 27:89-97; PMID:24485523; 10.1016/j.coi.2014.01.002.
53. J.Cohen, M.Sznol. Therapeutic combinations of immune-modulating antibodies in melanoma and beyond. Semin Oncol 2015; 42:488-94; PMID:25965368; 10.1053/j.seminoncol.2015.02.014.
54. B.R.Rosborough, D.Raich-Regue, B.M.Matta, K.Lee, B.Gan, R.A.DePinho, H.Hackstein, M.Boothby, H.R.Turnquist, A.W.Thomson. Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1, and regulatory T-cell induction. Blood 2013; 121:3619-30; PMID:23444404; 10.1182/blood-2012-08-448290.
55. K.Lee, P.Gudapati, S.Dragovic, C.Spencer, S.Joyce, N.Killeen, M.A.Magnuson, M.Boothby. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 2010; 32:743-53; PMID:20620941; 10.1016/j.immuni.2010.06.002.
56. A.E.Morelli, A.F.Zahorchak, A.T.Larregina, B.L.Colvin, A.J.Logar, T.Takayama, L.D.Falo, A.W.Thomson. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood 2001; 98:1512-23; PMID:11520802; 10.1182/blood.V98.5.1512.
57. Y.Qu, L.Chen, A.D.Pardee, J.L.Taylor, A.K.Wesa, W.J.Storkus. Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment. J Immunol 2010; 185:2895-902; PMID:20675595; 10.4049/jimmunol.1001294.